v3.26.1
Collaboration and License Agreements (Tables)
12 Months Ended
Dec. 31, 2025
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Revenue by Collaboration Partners

The following table summarizes the revenue by collaboration partner:

 

 

 

Year Ended December 31,

 

 

 

2025

 

 

2024

 

 

 

(in thousands)

 

Amgen

 

$

9,819

 

 

$

3,054

 

Astellas

 

 

17,913

 

 

 

29,378

 

Bristol Myers Squibb

 

 

41,928

 

 

 

77,960

 

Regeneron

 

 

6,510

 

 

 

10,830

 

Moderna

 

 

31

 

 

 

16,881

 

Total revenue

 

$

76,201

 

 

$

138,103

 

Summary of Contract Liabilities

The following table presents changes in the Company’s total contract liabilities for the years ended in December 31, 2025 and 2024 (in thousands):

 

 

Deferred Revenue

 

 

(in thousands)

 

Balance at 12/31/2023

$

212,315

 

Additions

 

8,643

 

Revenue Recognized

 

(126,895

)

Balance at 12/31/2024

$

94,063

 

Additions

 

5,605

 

Revenue Recognized

 

(71,201

)

Balance at 12/31/2025

$

28,467